BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38462943)

  • 1. Acquired immune resistance is associated with interferon signature and modulation of KLF6/c-MYB transcription factors in myeloid leukemia.
    Parveen M; Karaosmanoglu B; Sucularli C; Uner A; Taskiran EZ; Esendagli G
    Eur J Immunol; 2024 May; 54(5):e2350717. PubMed ID: 38462943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of ZFAS1 suppresses the progression of acute myeloid leukemia by regulating microRNA-150/Sp1 and microRNA-150/Myb pathways.
    Gan S; Ma P; Ma J; Wang W; Han H; Chen L; Li X; Wu F; Sun H
    Eur J Pharmacol; 2019 Feb; 844():38-48. PubMed ID: 30502345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
    Armenteros-Monterroso E; Zhao L; Gasparoli L; Brooks T; Pearce K; Mansour MR; Martens JHA; de Boer J; Williams O
    Leukemia; 2019 Dec; 33(12):2817-2829. PubMed ID: 31138842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
    Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
    Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
    Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
    Elife; 2021 Feb; 10():. PubMed ID: 33527899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
    Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
    Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
    Munker R; Andreeff M
    Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
    Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
    Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
    Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
    Clesham K; Walf-Vorderwülbecke V; Gasparoli L; Virely C; Cantilena S; Tsakaneli A; Inglott S; Adams S; Samarasinghe S; Bartram J; Williams G; de Boer J; Williams O
    Leukemia; 2022 Jun; 36(6):1541-1549. PubMed ID: 35368048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression.
    Zhang J; Peng Y; He Y; Xiao Y; Wang Q; Zhao Y; Zhang T; Wu C; Xie Y; Zhou J; Yu W; Lu D; Bai H; Chen T; Guo P; Zhang Q
    Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166268. PubMed ID: 34536536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.
    Huang JC; Basu SK; Zhao X; Chien S; Fang M; Oehler VG; Appelbaum FR; Becker PS
    Blood Cancer J; 2015 Apr; 5(4):e302. PubMed ID: 25860293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow.
    Cao H; Kim DH; Howard A; Moz H; Wasnik S; Baylink DJ; Chen CS; Reeves ME; Mirshahidi S; Xiao J; Francis O; Marcucci G; Xu Y
    Neoplasia; 2021 Dec; 23(12):1252-1260. PubMed ID: 34775232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
    Pattabiraman DR; McGirr C; Shakhbazov K; Barbier V; Krishnan K; Mukhopadhyay P; Hawthorne P; Trezise A; Ding J; Grimmond SM; Papathanasiou P; Alexander WS; Perkins AC; Levesque JP; Winkler IG; Gonda TJ
    Blood; 2014 Apr; 123(17):2682-90. PubMed ID: 24596419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptidomimetic blockade of MYB in acute myeloid leukemia.
    Ramaswamy K; Forbes L; Minuesa G; Gindin T; Brown F; Kharas MG; Krivtsov AV; Armstrong SA; Still E; de Stanchina E; Knoechel B; Koche R; Kentsis A
    Nat Commun; 2018 Jan; 9(1):110. PubMed ID: 29317678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C/EBPα and MYB regulate FLT3 expression in AML.
    Volpe G; Walton DS; Del Pozzo W; Garcia P; Dassé E; O'Neill LP; Griffiths M; Frampton J; Dumon S
    Leukemia; 2013 Jul; 27(7):1487-96. PubMed ID: 23340802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
    Walf-Vorderwülbecke V; Pearce K; Brooks T; Hubank M; van den Heuvel-Eibrink MM; Zwaan CM; Adams S; Edwards D; Bartram J; Samarasinghe S; Ancliff P; Khwaja A; Goulden N; Williams G; de Boer J; Williams O
    Leukemia; 2018 Apr; 32(4):882-889. PubMed ID: 29089643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.